Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C GSK2251052 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single cohort | EXPERIMENTAL | 14C GSK2251052 |
| Name | Type | Description |
|---|---|---|
| 14C GSK2251052 | DRUG | 1500 mg iv dose GSK2251052 |
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the populat...
14C GSK2251052 is an investigational small molecule being developed for community-acquired infection. It is a radiolabeled form of GSK2251052, used in a Phase 1 mass balance study to track the drug's absorption, distribution, metabolism, and excretion in the body. It is not yet approved and remains in clinical development.
14C GSK2251052 is developed by GSK plc, traded on the New York Stock Exchange under the ticker GSK. The company is conducting clinical research on this investigational drug for the treatment of community-acquired infection.
14C GSK2251052 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is still in the early stages of clinical research.
14C GSK2251052 has one completed clinical trial, NCT01475695, titled "GSK2251052 Mass Balance in Healthy Adult Subjects." This Phase 1 study enrolled 6 healthy male volunteers in the Netherlands and was uncontrolled, meaning there was no comparator group.
14C GSK2251052 is a radiolabeled version of GSK2251052, where the carbon-14 isotope is incorporated into the molecule. This labeling allows researchers to track the drug's fate in the body during mass balance studies. The therapeutic agent itself is GSK2251052.